Candela Medical, which provides medical devices for aesthetic procedures, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Candela provides a broad range of medical devices for aesthetic applications including various lasers, including solid state, pulsed dye, non-ablative fractional, CO2, and picosecond, as well as intense pulsed light, radiofrequency, and microneedling devices. The company sells and markets its products directly in 18 countries, including the US, China, Japan, and Western Europe, as well as indirectly in 66 countries.
The Marlborough, MA-based company was founded in 2010 and booked $390 million in sales for the 12 months ended June 30, 2021. It plans to list on the Nasdaq under the symbol CDLA. Candela Medical filed confidentially on July 21, 2021. BofA Securities, Goldman Sachs, Barclays, Baird, Canaccord Genuity, and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
